PD-1 Inhibition in First-Line Prolongs Survival in Cervical Cancer
Updated findings of KEYNOTE-826, presented at the American Society of Clinical Oncology (ASCO) annual meeting, continued to demonstrate a significant survival benefit with the addition of pembrolizumab (Keytruda) to standard treatment for previously untreated recurrent or metastatic cervical cancer. In this exclusive MedPage Today video, Deanna Gerber, MD, of the NYU Long Island School of […]